预约演示

Arcus Biosciences to Present Data from Ongoing EDGE-Gastric Study at ASCO Plenary and to Report Third-Quarter Financial Results on November 7

2023-10-17

临床2期财报ASCO会议临床结果

Data from the A1 cohort of EDGE-Gastric, the Phase 2 study of domvanalimab, an Fc-silent anti-TIGIT monoclonal antibody, in first-line upper gastrointestinal cancers will be presented at the virtual ASCO Monthly Plenary Series by Yelena Y. Janjigian, M.D., Chief Gastrointestinal Oncology, Memorial Sloan Kettering Cancer Center on November 7, 2023 Arcus Biosciences will also report third quarter 2023 results and host a conference call aftermarket on November 7, 2023 HAYWARD, Calif.--(BUSINESS WIRE)-- Arcus Biosciences, Inc. (NYSE:RCUS) today announced that data from cohort A1 of the ongoing Phase 2 EDGE-Gastric study will be presented at the American Society of Clinical Oncology (ASCO) Monthly Plenary Series on November 7, 2023. EDGE-Gastric (also known as ARC-21), a collaboration between Arcus and Gilead Sciences, is a Phase 2 platform study evaluating various combinations of domvanalimab, an Fc-silent anti-TIGIT monoclonal antibody, and zimberelimab, an anti-PD-1 antibody, in patients with locally advanced unresectable or metastatic gastric (G), gastroesophageal junction (GEJ) or esophageal (E) adenocarcinoma. Cohort A1 evaluates the combination of domvanalimab plus zimberelimab and chemotherapy given as an initial treatment in approximately 40 patients. The ASCO Monthly Plenary Series is a virtual forum for presentation and discussion of the latest cancer research. According to ASCO, live presentations are accessible to virtual attendees and available on-demand, and abstract presentations are accompanied by a discussant presentation and followed by a live Q&A session. Abstracts accepted for the Monthly Plenary Session are also placed at the ASCO Annual Meeting in June 2024. Title: EDGE-Gastric Arm A1: Phase 2 study of domvanalimab, zimberelimab, and FOLFOX in first-line (1L) advanced gastroesophageal cancer. Presenter: Yelena Y. Janjigian, M.D., Chief, Gastrointestinal Oncology, Memorial Sloan Kettering Cancer Center Date: Tuesday, November 7, 2023 Time: 12:00 p.m. – 1:00 p.m. PT / 3:00 p.m. – 4:00 p.m. ET Webcast: The livestream presented by ASCO is free to register on their website. In addition, Arcus will release third quarter results and pipeline updates after market close on November 7, 2023. Following the release, Arcus management will host a conference call to discuss the financial results, EDGE-Gastric results and other pipeline updates. Date: Tuesday, November 7, 2023 Time: 2:00 p.m. PT / 5:00 p.m. ET Investors interested in listening to the conference call may do so by dialing (646) 904-5544 (local) or (833) 470-1428 (toll-free), using Conference ID: 258096. To access the live webcast and accompanying slide presentation, please visit the “Investors & Media” section of the Arcus Biosciences website at . A replay will be available following the live event. About EDGE-Gastric The ongoing, multi-arm, global EDGE-Gastric trial (NCT05329766) is evaluating the safety and efficacy of various combinations of the Fc-silent anti-TIGIT antibody domvanalimab and the anti-PD-1 antibody zimberelimab in patients with locally advanced unresectable or metastatic gastric (G), gastroesophageal junction (GEJ) or esophageal (E) adenocarcinoma. Patients with previously untreated G/GEJ/E adenocarcinoma received 1600 mg of domvanalimab intravenously (IV) every four weeks (Q4w) plus 480 mg of zimberelimab IV Q4W + FOLFOX (oxaliplatin 85 mg/m2 IV, leucovorin 400 mg/m2 IV, fluorouracil 400 mg/m2 IV bolus + 2400 mg/m2 continuous 46-48-hour IV infusion) every two weeks. About Arcus Biosciences Arcus Biosciences is a clinical-stage, global biopharmaceutical company developing differentiated molecules and combination medicines for people with cancer. In partnership with industry partners, patients and physicians around the world, Arcus is expediting the development of first- or best-in-class medicines against well-characterized biological targets and pathways and studying novel, biology-driven combinations that have the potential to help people with cancer live longer. Founded in 2015, the company has expedited the development of multiple investigational medicines into clinical studies, including new combination approaches that target TIGIT, PD-1, the adenosine axis (CD73 and dual A2a/A2b receptor) and HIF-2a. For more information about Arcus Biosciences’ clinical and pre-clinical programs, please visit or follow us on Twitter.